SCHEMBL30965461

SCHEMBL30965461

Oc1ncc(-c2ccc(-c3cnc4cc(Cl)ccc4n3)cc2)nc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
KDR P35968 2/20 0.48
FGFR3 P22607 1/20 0.48
BCHE P06276 1/20 0.47
TLR9 Q9NR96 1/20 0.44
HPGD P15428 2/20 0.43
ADORA3 P0DMS8 1/20 0.42
CYP2C9 P11712 2/20 0.41
PTGES O14684 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALOX5 P09917 1/20 0.41
CASP7 P55210 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 1/20 0.40
RIPK1 Q13546 1/20 0.40
PARP1 P09874 1/20 0.40
HRH4 Q9H3N8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25045587 1.00 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL30107670 0.89 NPC1 (0.68) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL15850502 0.89 NPC1 (0.68) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL30665751 0.88 BCHE (0.63) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL27323740 0.88 BCHE (0.63) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL30965470 0.83 GRIN2B (0.39) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL25045588 0.83 GRIN2B (0.39) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL30965473 0.82 ALOX5 (0.53) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL25045580 0.82 ALOX5 (0.53) NPC1RAB9ASMN1; SMN2KDRFGFR3
SCHEMBL10555895 0.82 NPC1 (0.51) NPC1RAB9ASMN1; SMN2KDRFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 NPC1 1454/4885RAB9A 701/4885SMN1; SMN2 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.